Pemetrexed

Pemetrexed (LY231514) is an antifolate, the Ki values of the pentaglutamate of Pemetrexed (LY231514) are 1.3, 7.2, and 65 nM for inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), respectively[1].

Product Specifications

CAS Number

[137281-23-3]

Product Name Alternative

LY231514

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H341, H351, H360, H361, H372, H373, H412

Target

Antifolate; Autophagy

Type

Reference compound

Related Pathways

Autophagy; Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/pemetrexed.html

Purity

99.95

Solubility

DMSO : 250 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C1NC(N)=NC2=C1C(CCC3=CC=C(C(N[C@H](C(O)=O)CCC(O)=O)=O)C=C3)=CN2

Molecular Formula

C20H21N5O6

Molecular Weight

427.41

Precautions

H302, H315, H319, H341, H351, H360, H361, H372, H373, H412

References & Citations

[1]Shih C, et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997 Mar 15;57 (6) :1116-23.|[2]Anraku M, et al. Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignantmesothelioma. J Immunol. 2010 Jul 15;185 (2) :956-66.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

Launched

Citation 01

ACS Appl Mater Interfaces. 2025 Oct 8;17 (40) :55861-55875.|Acta Pharmacol Sin. 2021 Jan;42 (1) :108-114.|Adv Ther. 2024 Jul 18.|Bioengineering (Basel) . 2025 Oct 19;12 (10) :1121.|Biol Methods Protoc. 2025 Feb 13;10 (1) :bpaf012.|bioRxiv. 2024 June 12.|bioRxiv. 2025 August 15.|bioRxiv. 2025 January 21.|bioRxiv. 2025 January 22.|Br J Cancer. 2023 Aug;129 (3) :531-540.|Cell Death Discov. 2022 Jul 5;8 (1) :307.|Cell Rep Med. 2023 Feb 21;4 (2) :100911.|Cell Rep Methods. 2023 Oct 23;3 (10) :100599.|Commun Biol. 2022 Jun 23;5 (1) :619.|Dev Cell. 2025 Sep 3:S1534-5807 (25) 00530-1.|Eur J Med Res. 2025 Aug 4;30 (1) :704.|Eur J Pharmacol. 2025 Apr 2:996:177584.|Heliyon. 2024 Nov 8;10 (22) :e40299.|Hum Cell. 2025 Apr 19;38 (3) :92.|Int Immunopharmacol. 2023 Nov 3;125 (Pt A) :111158.|Integr Cancer Ther. 2024 Jan-Dec:23:15347354241273962.|J Clin Invest. 2021 Aug 2;131 (15) :e138022.|J Control Release. 2023 Jan:353:490-506.|J Pharm Anal. 2024 Apr 25:100984.|Mol Cancer. 2024 Jan 10;23 (1) :12.|Pharmacol Res Perspect. 2020 Apr;8 (2) :e00575.|Pharmacol Res. 2024 May 9:204:107208.|Res Sq. 2025 Sep 7.|Research Square Print. September 27th, 2022.|Sci Rep. 2025 Oct 16;15 (1) :36227.|Theranostics. 2020 May 15;10 (13) :6048-6060.|Beilstein J Org Chem. 2017 Oct 25:13:2252-2263.|Clin Transl Oncol. 2022 Nov;24 (11) :2231-2240.|Faculty of the Graduate School of Biomedical Sciences. The University of Texas Southwestern Medical Center. Oct 1. 2015.|J Exp Clin Cancer Res. 2025 Oct 21;44 (1) :293.|J Mol Med (Berl) . 2019 Aug;97 (8) :1183-1193.|Mol Cell. 2019 Dec 5;76 (5) :838-851.e5.|Odontology. 2020 Apr;108 (2) :300-311.|J Mol Med (Berl) . 2019 Aug;97 (8) :1183-1193.